LMO2 Antibody / Rhombotin 2, 100 ug

LMO2 antibody detects LIM domain only protein 2, encoded by the LMO2 gene on chromosome 11p13. LMO2 antibody is commonly applied in research on hematopoiesis, transcriptional regulation, and cancer biology. LMO2 is a transcriptional co-regulator without intrinsic DNA-binding activity; instead, it functions as an adaptor protein that brings together DNA-binding transcription factors within multiprotein complexes. It plays essential roles in hematopoietic stem cell maintenance, vascular development, and T-cell differentiation. Expression is high in hematopoietic progenitors and endothelial cells, but tightly regulated, as dysregulation promotes oncogenesis.

Structurally, LMO2 is a small nuclear protein of ~158 amino acids containing two tandem LIM domains, zinc-binding motifs that mediate protein-protein interactions. These LIM domains allow LMO2 to interact with basic helix-loop-helix (bHLH) proteins such as TAL1, GATA1, and LDB1, forming complexes that regulate transcription of genes required for hematopoietic development. Alternative splicing generates isoforms with distinct interaction patterns.

Functionally, LMO2 acts as a bridging factor, linking transcription factors to DNA regulatory regions. It is essential for erythropoiesis and angiogenesis, controlling expression of genes involved in cell fate decisions. Knockout mice lacking LMO2 exhibit embryonic lethality due to failure of blood vessel and hematopoietic development. In hematopoietic stem cells, LMO2 ensures long-term maintenance and self-renewal. Researchers use LMO2 antibody to study transcriptional regulation in blood formation and cancer biology.

Clinically, LMO2 is a well-known oncogene in T-cell acute lymphoblastic leukemia (T-ALL), where aberrant expression drives leukemogenesis. Chromosomal translocations or retroviral insertional mutagenesis can activate LMO2, promoting proliferation of immature T-cells. It also has roles in diffuse large B-cell lymphoma and other hematologic malignancies. Conversely, in normal physiology, its expression serves as a marker for angiogenesis and hematopoietic stem cell activity. NSJ Bioreagents provides LMO2 antibody to support oncology and stem cell research.

Experimentally, LMO2 antibody is used in western blotting to detect the ~18 kDa protein, in immunohistochemistry to examine expression in hematopoietic and endothelial tissues, and in immunofluorescence microscopy to confirm nuclear localization. Co-immunoprecipitation with LMO2 antibody allows identification of transcriptional complexes and regulatory partners.